In Lancet Oncology this week, researchers in Europe and Canada explore the use of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer. The team did a meta-analysis of individual patient data from five randomized trials comparing anthracycline-based regimens with cyclophosphamide, methotrexate, and fluorouracil combination regimens. Data from 3,452 patients with HER2 markers and 3,102 patients with TOP2A markers showed that, although these markers may have some value in predicting whether a patient will respond to anthracycline-based chemotherapy, the findings don't support the use of anthracycline therapy alone in patients with HER2-amplified or TOP2A-aberrated tumors, the authors write.
Also in Lancet Oncology this week, researchers in Italy explore whether transurethral resection of bladder tumors is more effective for treating patients than combining the resection with pre- or post-surgical administration of the drug mitomycin. The team randomly assigned patients with invasive bladder cancer to three groups — 124 patients received bladder tumor resection only, 126 received immediate post-resection instillation of mitomycin, and another 124 received immediate pre-resection intravesical instillation of mitomycin. Patients receiving mitomycin before their surgery had a lower rate of recurrence and a higher disease-free interval than patients in the other two groups, the authors found.